![藥理學(xué)總論英文睢大員_第1頁(yè)](http://file4.renrendoc.com/view/798dc2e87a1e9c48999c3fe12c66ceae/798dc2e87a1e9c48999c3fe12c66ceae1.gif)
![藥理學(xué)總論英文睢大員_第2頁(yè)](http://file4.renrendoc.com/view/798dc2e87a1e9c48999c3fe12c66ceae/798dc2e87a1e9c48999c3fe12c66ceae2.gif)
![藥理學(xué)總論英文睢大員_第3頁(yè)](http://file4.renrendoc.com/view/798dc2e87a1e9c48999c3fe12c66ceae/798dc2e87a1e9c48999c3fe12c66ceae3.gif)
![藥理學(xué)總論英文睢大員_第4頁(yè)](http://file4.renrendoc.com/view/798dc2e87a1e9c48999c3fe12c66ceae/798dc2e87a1e9c48999c3fe12c66ceae4.gif)
![藥理學(xué)總論英文睢大員_第5頁(yè)](http://file4.renrendoc.com/view/798dc2e87a1e9c48999c3fe12c66ceae/798dc2e87a1e9c48999c3fe12c66ceae5.gif)
版權(quán)說(shuō)明:本文檔由用戶(hù)提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、藥理學(xué)總論英文睢大員 What is Pharmacology? Chapter 1 Introduction basic medicine Pharmacologypharmacy medicine clinic medicine - drug broadly defined as any chemical that affect living processes - useful in prevention, diagnosis, treatment of diseasesChapter 1 IntroductionWhat is a drug?Sources of DrugsAnimal
2、sPlants MineralsSyntheticsMicrobesGenetic engineering drugs基因工程藥物過(guò)程示意圖從細(xì)胞中分離出DNA限制酶截取DNA片斷分離大腸桿菌中的質(zhì)粒 DNA重組用重組質(zhì)粒轉(zhuǎn)化大腸桿菌培養(yǎng)大腸桿菌克隆大量基因 drugTask of PharmacologymedicinepharamacodynamicspharmacokineticsbodyDevelopment of Pharmacology上古時(shí)代公元前1世紀(jì)明代(公元1596年)近代藥理學(xué)的發(fā)展迄今Pharmacological research of new drugs pharm
3、acodynamics general pharmacology pharmacokinetics toxicitology 1、 preclinical testsafety pharmacologyPharmacological research of new drugs period : 2030 case period : 200300 case period : 400 case period : clinical trial2000 case2、 clinical pharmacological trial Section 1 Basic action of drugsChapte
4、r 2 Pharmacodynamicsstimulators or excitantsinhibitors or depressantsstimulation or excitation depression or inhibitiondrug action drug effect local action general action Chapter 2 Pharmacodynamicstherapeutic effect advers drug reactionselectivity dualismChapter 2 Pharmacodynamics Therapeutic effect
5、 etiological treatment symptomatic treatment Chapter 2 PharmacodynamicsAdvers drug reaction side action econdary reactiontoxic reactionacute toxcitychronic toxcitycarcinogenesisteratogenesismutagenesisallergic reactionresidual effect withdrawal reaction Section 2 Receptive theoryChapter 2 Pharmacody
6、namicsLigand (L)Effect (E)Receptor (R)Chapter 2 Pharmacodynamicsreceptor typechannel-linkd receptorsG-protein coupled receptorstyrosine kinase-linked receptorsregulate gene transcription receptors激動(dòng)藥結(jié)合區(qū)域膜外膜內(nèi)激動(dòng)藥結(jié)合區(qū)域 Ligand-gated ion channel receptorsG蛋白偶聯(lián)CN激動(dòng)藥結(jié)合區(qū)域膜外膜內(nèi) G-protein coupled recptors激動(dòng)藥結(jié)合區(qū)
7、域膜外膜內(nèi)催化結(jié)構(gòu)區(qū)域 Tyrosine-protein kinase receptor激動(dòng)藥結(jié)合區(qū)域膜外膜內(nèi)DNA結(jié)合區(qū)域轉(zhuǎn)錄激活區(qū)域載體 + 藥物載體-藥物復(fù)合物載體 + 藥物載體 Intracellular receptorsChapter 2 Pharmacodynamicsreceptorregulationdown regulationup regulationhomospecific regulationheterospecific regulationChapter 2 PharmacodynamicsLRintrinsic activityaffinityEChapter 2
8、 Pharmacodynamicsreceptor agonistfull agonistpartial agonistreceptor antagonist full antagonist partial antagonistcompetitive antagonistnon-competitive antagonistnon-competitive antagonistdrug action and signai transductionChapter 2 Pharmacodynamicsgraded responsequantal response Dose-response relat
9、ionshipChapter 2 Pharmacodynamicsminimum effective dose (threshold dose)maximum effect (Emax)maximal dose (Max-D)median effective dose (ED50) minimum toxic dose (Tmin)median lethal dose (LD50)Dose-response relationshipefficacypotencyDose-response relationship EmaxED50efficacypotency100%50%threshold
10、doseMax-DTminDose Response CurveEmaxEmaxChapter 2 Pharmacodynamics LD50therapeutic index (TI) = ED50 LD5safety index (SI) = ED95 (LD1 - ED99)safety margin (SM) = 100% ED99safety evaluation of drugsChapter 3 Pharmacokinetics absorptiondistributionmetabolism (biotransformation) excretionSection 1 phys
11、iological disposition of drugsPharmacokinetic PhaseeliminationAbsorptiondistribution excretiondrug transport through membranesmetabolismbiotransformation Cell membrane 1) GI epithelial cells 2) vascular endothelium 3) blood brain barrier (BBB) 4) subcellular membranes 一、Drug transport across membran
12、es1234GI epithelial cellsVascular endotheliumBlood brain barrier(BBB)Subcellular membranesA. simple diffusion1. Passive transportB. facilitated diffusionC. aqueous diffusionacross membraneof lipidacross aqueous channelcarrier transportoutsideinside1. Passive transport simple diffusion R = DA (C1 - C
13、2) / XR: diffusion rate D: diffusion constantA: area of membrane(C1-C2): concentration gradient of drugsX: thickness of membrane For a weak acid ka HA H+ + A- H+ A- ka = HA ka : dissociation constant pH = - log concentration H+ - log Ka is pKa For a weak acid A-pKa = pH -log HA A-pH - pKa = log HA10
14、 pH - pKa = A- / HAFor a weak base ka H+B BH+ H+ + B Ka = BH+ BH+ pKa pH = log B10 pka pH = BH+ / B For a weak acid unionized pKa = pH + log ionized 10 PH-pka = ionized / unionizedFor a weak base ionized pKa = pH + log unionized 10pka-pH= ionized / unionized If A-= HA or B=BH+ - pKa = pH - a substan
15、ce is half ionized and half nonionized Must be careful you must know pKa A-pH - pKa = log HA BH+or pKa pH = log B 2. active transport Examle : Na+-K+ ATPase 3. cytosis pinocytosisexocytosis 1. Absorption the movement of a drug from its site of administration into the bloodstream二、drug process in bod
16、yBloodstreamdrugdrug1) First-pass effectinfluencing factor the first pass effect can be avoided by sublingual rectum inhalation im sc GI hepatic portal vein liver vena cava 2) Bioavailability fraction of an administered drug that reaches the systemic circulation for IV, Minimum effective concentrati
17、on 2. DistributionBloodstreamdrugdrug enters the extracellular fluids and tissues of the bodydrugcell 1) binding of drug by plasma proteinsinfluencing factor2) bloodstream of organ3) affinity of tissue4) blood brain barrier5) placental barrier Apparent Volume of Distribution (Vd)Vd is hypothetical v
18、olume Vd = A / C 3. Metabolism two phases oxidationsreductionshydrolyses the first phase conjugationsthe second phaseHepatic microsomal enzymesenzyme inhibitorenzyme inducermixed function oxidases 4. Excretion excretion of kidneysexcretion of bileexcretion of mammary gland Hepatoenteral circulation
19、liver-bilegall bladder duodenumexcrete 4. Excretion 消除transport and transformation of drugs Section 2 Basic concept of pharmacokineticsA. Time-concentration curvethreshold dose CmaxTpeakTCmin B. Half Life (t1/2) first order kinetics t1/2 zero order kinetics t1/2 C. Compartment model absoption elimin
20、ationDrug one-compartment modeltwo-compartment model drug central compartment peripheralcompartmentabsoptionelimination D. Clearance (CL)CL = Vd . K or1/20210123456Steady stateconCss.maxCss.min7 E. Steady state concentration (Css) 血藥濃度100200300802460002468100200300時(shí)間(半衰期)10020030002460ABC8MTCMEC三種不同
21、給藥方案對(duì)穩(wěn)態(tài)濃度的影響A. 縮短給藥時(shí)間 B. 增加給藥劑量 C. 負(fù)荷量給藥F. Drug elimination rate dc/dt = -KCn C: concentration of the drug K: elimination rate constantn=1 first order kinetics -dc/dt = KC1n=0 zero order kinetics -dc/dt = KC0 = VmaxFirst order kinetics: constant fraction of drug is eliminated per unit timeZero order
22、 kinetics : same quantity of drug is eliminated per unit timeRoutes of Drug Administrationcommon abbreviationspo = per os = oraliv = intravenous = into the veinim = intramuscular = into the musclesc = subcutaneous = between the skin and muscleip = intraperitoneal = within the peritoneal cavityicv =
23、intracerebroventricular =directly into the ventricle of the brainChapter 4 Factors affecting effect of drugs age and sexmental and pathologic factorsindividual variation and genetics species variationSection 1 Factors about organism aspect age and sexage infants aged people age and sexsexmalefemalem
24、ental factor spirit and body diseasebody and spirit diseaseplacebo actions mental and pathologic factors mental and pathologic factorspathologic factordystrophyrenal inadequacyhepatic inadequacyindividual variation and genetic factorsindividual variationhypersensitive reactiontolerancehypersensitivityindividual variation and genetic factorsgenetic factors haemolyticus anemiamalig anemiamethemoglobinemiaspecies variationanimalrace Chapter 4 Factors affecting effect of d
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶(hù)所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶(hù)上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶(hù)上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶(hù)因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 環(huán)保行業(yè)采購(gòu)工作經(jīng)驗(yàn)分享
- 2025-2030全球鍍鎳服務(wù)行業(yè)調(diào)研及趨勢(shì)分析報(bào)告
- 2025-2030全球液密柔性非金屬導(dǎo)管行業(yè)調(diào)研及趨勢(shì)分析報(bào)告
- 2025-2030全球水電解用全氟磺酸膜行業(yè)調(diào)研及趨勢(shì)分析報(bào)告
- 2025年全球及中國(guó)半自動(dòng)焊接機(jī)行業(yè)頭部企業(yè)市場(chǎng)占有率及排名調(diào)研報(bào)告
- 2025年全球及中國(guó)癸二酸二酰肼行業(yè)頭部企業(yè)市場(chǎng)占有率及排名調(diào)研報(bào)告
- 2025-2030全球小尺寸工業(yè)平板電腦行業(yè)調(diào)研及趨勢(shì)分析報(bào)告
- 2025年全球及中國(guó)二氧化碳捕獲機(jī)行業(yè)頭部企業(yè)市場(chǎng)占有率及排名調(diào)研報(bào)告
- 2025年全球及中國(guó)叉車(chē)機(jī)器人行業(yè)頭部企業(yè)市場(chǎng)占有率及排名調(diào)研報(bào)告
- 2025-2030全球制藥用乙酰氯行業(yè)調(diào)研及趨勢(shì)分析報(bào)告
- QFD模板含計(jì)算公式計(jì)分標(biāo)準(zhǔn)說(shuō)明模板
- 醫(yī)院護(hù)理培訓(xùn)課件:《早產(chǎn)兒姿勢(shì)管理與擺位》
- 《論文的寫(xiě)作技巧》課件
- 國(guó)有資產(chǎn)管理辦法-國(guó)有資產(chǎn)管理辦法條例
- 00015-英語(yǔ)二自學(xué)教程-unit3
- 第二章共混改性基本原理
- 碳納米管及其應(yīng)用課件
- 病故軍人證明書(shū)如何辦理
- 企業(yè)合規(guī)管理實(shí)務(wù)
- 安宮牛黃丸課件
- GB/T 21117-2007磁致伸縮液位計(jì)
評(píng)論
0/150
提交評(píng)論